# Study of Acalabrutinib and Tafasitamab in MZL Patients

> **NCT04646395** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **International Extranodal Lymphoma Study Group (IELSG)** · enrollment: 26 (actual)

## Conditions studied

- Marginal Zone Lymphoma

## Interventions

- **DRUG:** Tafasitamab
- **DRUG:** Acalabrutinib

## Key facts

- **NCT ID:** NCT04646395
- **Lead sponsor:** International Extranodal Lymphoma Study Group (IELSG)
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-10-20
- **Primary completion:** 2027-09-15
- **Final completion:** 2028-03-15
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2026-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04646395

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04646395, "Study of Acalabrutinib and Tafasitamab in MZL Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04646395. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*